These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16026246)

  • 21. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
    McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
    Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 immunogen (remune).
    Newsline People AIDS Coalit N Y; 1998 Dec; ():36. PubMed ID: 11367099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AIDS vaccine boosts immunity in HIV patients.
    RN; 1991 Oct; 54(10):103. PubMed ID: 1925340
    [No Abstract]   [Full Text] [Related]  

  • 25. Antibodies to HIV-1: aiming at the right target.
    Eggink D; Melchers M; Sanders RW
    Trends Microbiol; 2007 Jul; 15(7):291-4. PubMed ID: 17566740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
    Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
    Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV vaccine: hopes and hurdles.
    Chhatbar C; Mishra R; Kumar A; Singh SK
    Drug Discov Today; 2011 Nov; 16(21-22):948-56. PubMed ID: 21889604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV vaccine rationale, design and testing.
    Slobod KS; Coleclough C; Bonsignori M; Brown SA; Zhan X; Surman S; Zirkel A; Jones BG; Sealy RE; Stambas J; Brown B; Lockey TD; Freiden PJ; Doherty PC; Blanchard JL; Martin LN; Hurwitz JL
    Curr HIV Res; 2005 Apr; 3(2):107-12. PubMed ID: 15853717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibody responses to HIV-1 infection.
    Morris L
    IUBMB Life; 2002; 53(4-5):197-9. PubMed ID: 12120994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with therapeutic AIDS vaccines.
    Bourinbaiar AS; Abulafia-Lapid R
    Expert Rev Vaccines; 2005 Jun; 4(3):289-304. PubMed ID: 16026245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of the polyvalent approach to HIV-1 vaccine development.
    Hurwitz JL; Slobod KS; Lockey TD; Wang S; Chou TH; Lu S
    Curr Drug Targets Infect Disord; 2005 Jun; 5(2):143-56. PubMed ID: 15975020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational modifications of HIV-1 envelope glycoproteins for immunogen design.
    Phogat S; Wyatt R
    Curr Pharm Des; 2007; 13(2):213-27. PubMed ID: 17269929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Design, development and successful application of safe and effective HIV therapeutic and prophylactic vaccines].
    Abalaka JO
    Zhonghua Nan Ke Xue; 2005 Jan; 11(1):8-16. PubMed ID: 15704674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV vaccines 1983-2003.
    McMichael AJ; Hanke T
    Nat Med; 2003 Jul; 9(7):874-80. PubMed ID: 12835708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral sequence diversity: challenges for AIDS vaccine designs.
    McBurney SP; Ross TM
    Expert Rev Vaccines; 2008 Nov; 7(9):1405-17. PubMed ID: 18980542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines.
    McBurney SP; Ross TM
    Curr Pharm Des; 2007; 13(19):1957-64. PubMed ID: 17627529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A boost for the immune system.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.
    Pantaleo G; Koup RA
    Nat Med; 2004 Aug; 10(8):806-10. PubMed ID: 15286782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.